Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20628420

DOI
10.3129/i10-047

Indexing Status
Subject indexing assigned by NLM

MeSH
Antibodies, Monoclonal /administration & dosage /economics; Antibodies, Monoclonal, Humanized; Canada; Choroidal Neovascularization /drug therapy /economics; Cost-Benefit Analysis; Health Care Costs; Humans; Markov Chains; National Health Programs; Quality-Adjusted Life Years; Ranibizumab; Wet Macular Degeneration /drug therapy /economics

AccessionNumber
22010001228

Date bibliographic record published
10/11/2010